55218-69-4

Basic information

• Product Name: Pyridine, 2-methyl-4-(4-nitrophenyl)-
• CAS NO: 55218-69-4
• Molecular Formula: C12H10N2O2
• Molecular Weight: 214.224
• Mol File: 55218-69-4.mol
• Article Data: 7

Chemical Properties

• CAS DataBase Reference: Pyridine, 2-methyl-4-(4-nitrophenyl)-(CAS DataBase Reference)
• NIST Chemistry Reference: Pyridine, 2-methyl-4-(4-nitrophenyl)-(55218-69-4)
• EPA Substance Registry System: Pyridine, 2-methyl-4-(4-nitrophenyl)-(55218-69-4)

Safety Data

• Hazardous Substances Data: 55218-69-4(Hazardous Substances Data)

Upstream product

• 100-00-5 4-chlorobenzonitrile 
• 579476-63-4 2-methylpyridine-4-boronic acid 
• 586-78-7 para-nitrophenyl bromide 
• 660867-80-1 2-methyl-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridine 
• 22282-99-1 4-bromo-2-methylpyridine 
• 636-98-6 p-nitrobenzene iodide 

Downstream Products

• 216059-91-5 4-(2-methylpyridin-4-yl)phenylamine 

Relevant articles and documents

BICYCLIC KINASE INHIBITORS AND USES THEREOF

The invention relates to kinase inhibitors, in particular inhibitors of protein kinases including the SIK-family, CSF1R, HCK, TEK-family, BRK, ABL, KIT and/or their mutants. Although structurally similar to other bicyclic kinase inhibitors, the kinase inhibitors of the invention are distinctive; possessing a particular class of heterocyclic moiety. Such kinase inhibitors can display one or more certain properties distinct to their structurally similar kinase inhibitors. The kinase inhibitors of the invention or pharmaceutical compositions comprising them may be used in the treatment of a disorder or condition, such as a proliferative disorder, for example, a leukaemia or solid tumour. In particular, these and other structurally related kinase inhibitors may be used in the treatment of a proliferative disorder - such as a mixed phenotype acute leukaemia (MPAL) - characterised by (inter-alia) the presence of MEF2C protein, a human chromosomal translocation at 11q23, and/or a KMT2A fusion oncoprotein. The kinase inhibitors or pharmaceutical compositions of the invention may be used topically to modulate skin pigmentation in a subject, for example to impart UV protection and reduce skin cancer risk.

Wnt signal pathway inhibitor and use thereof

The invention relates to heterocyclic compounds with Wnt signal channel inhibition activity, particularly including compounds, pharmaceutically acceptable salts, various isotopes, various isomers or various crystal structures thereof having a structure represented by a general formula I (shown in the specification). By the compounds and a composition of the compounds, a Wnt signal channel can be effectively inhibited and diseases related to the Wnt signal channel can be treated or prevented.

NOVEL SUBSTITUTED TRIAZOLE DERIVATIVES AS GAMMA SECRETASE MODULATORS

The present invention is concerned with novel substituted triazole derivatives of Formula (I) wherein Het1, R1, R2, A1, A2, A3, A4, L1, and L2 have the mean